Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.
The therapeutic drug resources available to dermatologists have expanded and encompass off-label use of other drugs as well. As these new resources are employed, it is important to remain vigilant of possible drug interactions and toxicities contingent upon inter-individual variability of plasma drug levels. This article reviews the biochemistry of CYP enzymes and the clinical implications of genetic polymorphisms as relating to certain dermatologic drugs. In addition, we discuss the potential clinical function of cutaneous CYP enzymes.
Albert Einstein College of Medicine, Bronx, New York, USA. sarika.saggar@gmail.com
Sarika
S
Saggar
Howard I
HI
Maibach
D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D003880:Dermatology / Q000639:trends*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*; D011110:Polymorphism, Genetic; D011358:Product Surveillance, Postmarketing; D012867:Skin / Q000201:enzymology*
D065607:Cytochrome P-450 Enzyme Inhibitors; D003879:Dermatologic Agents; D004791:Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System